Cytomegalovirus: Genetics of drug resistance

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 135-143

  Biron, Karen K ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; NUCLEOSIDE ANALOG; VALACICLOVIR; VIDARABINE;

AIDS RELATED COMPLEX; AMINO ACID SUBSTITUTION; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RETINITIS; VIRUS GENE; VIRUS RESISTANCE;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0029864630     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_14     Document Type: Conference Paper

References (44)

1. Mocarski ES Jr. Cytomegalovirus biology and replication. The Human Herpesviruses ed. B Roizman, RJ Whitley, C Lopez, Raven Press Ltd., NY, 1993.
2. Drew WL, Sweet ES, Miner RC, Mocarski ES. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: Documentation by Southern Blot Hybridization. J Infect Dis 1984;150:952-953.
3. Chou S. Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Virol 1990;162:738-742.
4. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC, Deamond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-719.
5. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-293.
6. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991;163:1348-1351.
7. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance of ganciclovir. Antimicrob Agents Chemother 1991;35:2191-2197.
8. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9(-1,3,dihydroxy-2-propoxymethyl) guanine. J Infect Dis 1985;152:833-834.
9. Drew WL, Miner RC, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diag Vir 1993;1:179-185.
10. Gerna G, Baldanti F, Zavattoni M, Sarasini A, Percivalle E, Revello MG. Monitoring of ganciclovir sensitivity of human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antivir Res 1992;19:333-345.
11. Sullivan V, Talarico CL, Stantat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-164.
12. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-162.
13. Mar EC, Chiou JF, Cheng YC, Huang ES. Inhibition of cellular DNA polymerase a and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxy-ethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxy-metriyl)guanine. J Virol 1985;53:776-780.
14. Neyts J, Snoeck R, Schols D, Balzarini J, DeClercq E. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihyroxy-2-propoxymethyl)guanine (DHPG). Virology 1990;179:41-50.
15. Field, AK, Biron KK. "The end of innocence" revisited: Resistance of herpesviruses to antiviral drugs. Clin Microbiol Reviews 1994;7:1-13.
16. Larder BA, Kemp SD, Darby G. Related functional domains in virus DNA polymerases. EMBO J 1987;6:169-175.
17. Coen DM. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 15:287-300.
18. Biron KK, Stanat SC, Fyfe JA, Roberts G, Ostrove J, Short S, Gaillard R. Genetic heterogeneity in a drug-resistant VZV isolate recovered from an AIDS patient. 14th International Herpesvirus Workshop, Nyborg, Denmark, August 1989,p 248.
19. Gaillard R, Short S, Gaillard M, Stanat, S, Biron K. Sequence alterations in the DNA polymerase genes of VZV strains selected for in vitro resistance to acyclovir or phosphonoacetic acid. 15th International Herpesvirus Workshop, Georgetown Univ., Washington, DC August 1990;p 154.
20. Stanat SC, Talarico CL, Safrin S, Biron KK. Sequential varicella zoster virus isolates from an AIDS patient: Phenotypic and genetic evidence for evolution of drug resistance at the thymidine kinase and DNA polymerase loci. Antiviral Res 1992;17:(Suppl 1), p 51.
21. Sullivan V, Coen DM. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 1991;164:781-784.
22. D'Aquila RT, Summers WC. Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus. J Virol 1987;61:1291-1295.
23. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance of other DNA polymerase inhibitors. J Infect Dis 1992;166:904-907.
24. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66:7146-7152.
25. Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Possi LM, Coen DM. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethozyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
26. Lurain NS, Penland LK, Thompson KD. Ganciclovir-resistant DNA polymerase mutants isolated from an HCMV clinical specimen. The 19th International Herpesvirus Workshop 1994; Abstract 211.
27. Knox, KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991;337:1292-1293.
28. Leport C, Puget S, Pepin JM, et al. Cytomegalovirus resistant to foscarnet: Clinicovirologic correlation in patient with human immunodeficiency virus. J Infect Dis 1993;168:1329-1330.
29. Birch, CJ, Tachedijian G, Doherty R, Hayes K, Gust I. Altered Sensitivity to Antiviral Drugs of Herpes Simplex Virus Isolates from a Patient with the Acquired Immunodeficiency Syndrome. J Infect Dis 1990;162:731-734.
30. Chee MS, Lawrence GL, Barrell BG. Alpha-, beta- and gamma herpesviruses encode a putative phosphotransferase. J Gen Virol 1989;70:1151-1160.
31. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988;241:42-52.
32. Smith RF, Smith TF. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J Virol 1989;63:450-455.
33. Coulter LJ, Moss HWM, Lang J, McGeoch DJ. A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J Gen Virol 1993;74:387-395.
34. Purves FC, Roizman. The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein μ22. Proc Natl Acad Sci USA 1992;89:7310-7314.
35. Purves FC, Ogle WO, Roizman. Processing of the herpes simplex virus regulatory protein μ22 mediated by the UL13 protein kinase determines the accumulation of a subset of μ and g mRNAs and proteins in infected cells. Proc Natl Acad Sci USA 1993;90:6701-6705.
36. Ng TI, Keenan L, Kinchington PR, Grose C. Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol 1994;68:1350-1359.
37. Overton H, McMillan D, Hope L, Wong-Kai-In P. Production of host shutoff-defective mutants of herpes simplex virus type 1 by inactivation of the UL13 gene. Virol. 1994;202:97-106.
38. Wolf DG, Spector SA. Central nervous system (CNS) infection with ganciclovir-resistant human cytomegalovirus (CMV) in AIDS patients determined by analysis of the UL97 gene in cerebrospinal fluid. Abstracts of the 34th ICAAC, University of California, San Diego, La Jolla, CA.
39. Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC, Biron KK. Analysis of the UL97 Phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-583.
40. Lurain N, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994;68:4427-4431.
41. Wolf DG, Smith IL, Lee DJ, Salunga RC, Spector SA. Molecular basis of human cytomegalovirus ganciclovir resistance: Analysis of the UL96 open reading frame in clinical isolates. Interscience Conference on Antimicrob Agents & Chemother, New Orleans, Louisiana, 1993; Abstract 1200.
42. Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, Furione M, Bono F, Palu G, Gerna G. A three nucleotide-deletion in the UL97 ORF is responsible for the ganciclovir resistance of human cytomegalovirus clinical isolate. J Virol 1994; Submitted.
43. Hanson MH, Erice A, Talaico CL, Preheim LC, Biron KK, Stanat SC, Balfour HH, Jr. Characterization of a novel mutation in the UL97 gene of a clinical cytomegalovirus (CMV) strain conferring resistance to ganciclovir (GCV). Abstracts of the 34th ICAAC, University of Minnesota Medical School, MN; Burroughs Wellcome Co., NC and VA Medical Center, Omaha, NE.
44. Knighton DR, Zheng J, Eyck LFT, Xuong N-H, Taylor SS, Sowadski JM. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 1991;253:414-420.